Kornimate/medical-research-clean huggingface dataset:
pressure ulcer prevention: a turn and positioning system combined with incontinence care and tailored/standard repositioning

Conditions: Pressure Ulcers; Incontinence-associated Dermatitis

Summary: the prevalence of pressure ulcer in hospitals is 7,3% - 23%. the primary etiological factors are pressure or pressure combined with shear. prevention is very important and comprises: preventive skin care including cleansing and protecting the skin from exposure to moisture, the systematic repositioning of the patient, the offloading of the heels from the surface of the bed, the use of adequate bed support surfaces and an adequate nutritional status. the development and implementation of a risk based prevention plan for individuals identified as being at risk is strongly recommended. limited compliance exists towards pressure ulcer preventive interventions. 25,5% of the patients at risk receive fully adequate prevention in bed. the reposition frequence is adequate in 55% of patients at risk. there is a lack of rigorously performed research addressing the effectiveness of devices or risk based protocols to improve compliance. health care budgets are limited, priorities should be set in the allocation of health care resources. the primary aim of this study is to compare the effectiveness of the turn and position system (prevalon®turn and position system 2.0, sage) versus standard care to improve reposition frequence in patients at risk. the second aim is to compare the effectiveness of a tailored protocol versus standard care to improve reposition frequence in patients at risk. the third aim is to compare the effectiveness of standardized incontinence care versus standard care to improve the incidence of pressure ulcers and incontinence-associated dermatitis (iad). also a health economic evaluation will be performed. the study will be performed in hospital setting (university and general hospitals) in a random sample of 226 patients aged \> 18 who are at risk of developing pressure ulcers. patients will be recruited from three types of wards: intensive care units, geriatric wards and rehabilitation wards. patients will be included in the study for a period of 8 days.


Eligibility criteria:
inclusion criteria: * at risk of developing pressure ulcers (braden score \< 17) * maximum 24hours admitted on the ward at the time of inclusion * expected lenght of stay: 8 days * free of pressure ulcers category ii, ii, iv and incontinence-associated dermatitis (iad) category 2 at the start of the study exclusion criteria: - patients with no active or supportive therapy

Keywords: repositioning incontinence care prevention
feasibility of immunotherapy administration to patients with bronchial cancer in a hospital-at- home setting (imhadom)

Conditions: Bronchial Cancer

Summary: this observational prospective monosite study aims to describe, for the first time, management in a hospital-at-home programme of patients treated by immunotherapy for bronchial cancer. the feasibility in good conditions of this management, the patients' quality of life and their satisfaction will be evaluated.

those last years, immunotherapy treatment for bronchial cancers allowed considerable progress in terms of tumoral answer, survival without progression and global survival. usually administered in the day hospitalization department, its preparation and administration to the patient are compatible with hospital-at-home management. currently, this offer of care is rarely proposed, and only in particular situations. at the hospital of pau, it was introduced recently. it is proposed to patients who have been receiving immunotherapy for at least 4 months. at the moment, there is no study stating the feasibility of home hospitalization for patients treated by immunotherapy. given that there is neither regulatory obstacle nor any contraindication to care in home hospitalization, the choice of a descriptive study stands out. this study will be proposed to all the patients for whom home hospitalization has been decided and scheduled by the healthcare team in a medical staff meeting. the patients included in the study will be followed according to the common practice: a consultation every 3 months during 1 year.

Eligibility criteria:
inclusion criteria: * patients aged 18 and over. * with bronchial cancer treated with immunotherapy, * having two assessments of the response to immunotherapy received in day hospitalization with efficiency (stability or partial response) * without any graded higher than 1 adverse effects, or uncontrolled grade 1 adverse effects related to immunotherapy * eligible for a home-based hospitalization exclusion criteria: * patient receiving immunotherapy via temporary authorization for use, * frail patients requiring a frequent medical assessment thus day hospitalization cares

Keywords: immunotherapy, bronchial cancer, home-based hospitalization
impact of robotic surgery on systemic immune-inflammation index

Conditions: Gastric Cancer

Summary: robotic surgery has been gaining attention because of the physical and metabolic morbidity of the conventional open technique.the systemic immune-inflammation index(sii) has emerged as a recent and more reliable biomarker.in our single-center retrospective cohort study, the investigators investigate sii in robotic gastrectomy in order to show the advantageous effect on immune system which the investigators think as the first study in the literature.

patients who underwent robotic gastrectomy between january 2021 and september 2024 were included in the study. the primary outcome was to ascertain the beneficial effects of robotic surgery in gastric cancer patients in terms of immune response. the secondary outcome was to examine the reliability of sii as a serum biomarker in comparison to previous studies on the diagnosis and postoperative follow-up of gastric cancer.

Eligibility criteria:
inclusion criteria: gastric cancer patients treated with surgery exclusion criteria: patients with haematologic malignancy, immune system disorder, antiplatelet drug usage, operations including splenectomy

Keywords: gastric cancer minimally invasive gastrectomy systemic immune-inflammation index robotic surgery
investigation on a topical cosmetic pain lotion (egyfil) for stiffness and pain relief

Conditions: Pain; Muscle Rigidity

Summary: the application of a novel topical formulation for the treatment of muscular pain and stiffness (egyfil), containing hyaluronic acid, sh-polypeptide-6 and sh-oligopeptide-1, is investigated to evaluate efficacy and safety in 26 patients with stiffness and pain. single-arm, pre-market, interventional study.

26 male and female patients, ranging from 24 to 78 years old, will receive egyfil pain lotion given for the treatment of pain and stiffness over a three-days period. the primary objective of the study is to evaluate the clinical performance of the lotion in providing relief from stiffness, reduced mobility, and muscle tension pain.

Eligibility criteria:
inclusion criteria: 1. signed participants informed consent form (icf); 2. male or female, aged \> 18 years at the time of the signature of icf; 3. 3 to 10 rating according to the numerical rating scale (nrs), applied in participants with muscle tension pain; 4. willing to follow all study procedures; 5. willing to follow indications. exclusion criteria: 1. use of analgesics within the 24 hours prior to v1; 2. damaged skin in the area of treatment; 3. infective or prior inflammatory processes near the area of treatment; 4. ongoing cutaneous allergies; 5. serious and chronical pathological skin conditions (i.e., rosacea, psoriasis, vitiligo) including diagnosticated cancer with/without ongoing antitumor therapy; 6. allergy to lotion components (aqua (water), glycerin, caprylic/capric triglyceride, aloe barbadensis leaf juice powder, simmondsia chinensis seed oil (simmondsia chinensis (jojoba) seed oil), phenoxyethanol, ammonium acryloyldimethyltaurate/vp copolymer, carbomer, tocopheryl acetate, tocopherol, benzoic acid, sodium hydroxide, sodium hyaluronate, dehydroacetic acid, ethylhexylglycerin, butyrospermum parkii butter (butyrospermum parkii (shea butter)), sorbitol, sh-polypeptide 6; sh-oligopeptide-1 7. immune system illnesses; 8. uncontrolled systemic diseases; 9. known drug and/or alcohol abuse; 10. mental incapacity that precludes adequate understanding or cooperation; 11. participation in another investigational study.
multicenter phase ii study of sentinel node detection in squamous cell carcinoma t1-t2n0 of the oropharynx treated with radiotherapy and larynx treated by surgery, laser or robot

Conditions: Head and Neck Cancer

Summary: fifty patients with squamous cell carcinoma of the larynx t1 or t2n0 will therefore have a 99mtc lymphoscintigraphy per operative. the identified sentinel node will be removed along with the other lymph nodes of the selective group ii and iii recess. sentinel lymph node staging alone and complete dissection with routine anatomical pathology will be compared if this technique is reliable it will make a therapeutic de-escalation in the treatment of small tumors of the larynx by limiting the ganglionic gesture in the patients whose sentinel node is free from metastasis and also to better choose the treatment in case of lymph node involvement


Eligibility criteria:
inclusion criteria: 1. squamous cell carcinoma t1 or t2 of the oropharynx or larynx, clinical and computed tomography, m0, 2. previously untreated patient, without further concomitant localization, 3. patient over age 18 with no upper age limit, general condition who 0 or 1, life expectancy greater than 2 years, 4. on the cervical tomodensitometric assessment with injection of contrast agent: absence of adenomegaly suspicious of metastasis = ganglion of size less than one centimeter and 1.5 cm for group iia, ovoid, homogeneous, not taking the contrast product and no signs of peri-ganglion invasion (fatty hyperdensity, vascular adhesion), absence of ganglionic grouping (\> 3) 5. untreated patient outside a biopsy excision (melanoma experiment), 6. possibility of realizing an imrt 7. informing the patient and signing informed consent. exclusion criteria: 1) patient already treated for this tumor outside a biopsy excision, 2) contraindications to radiotherapy, scintigraphy or procedure, allergy to rhenium sulphide or 99m technetium 3) history of epidermoid carcinoma of vads 4) pregnant woman, likely to be pregnant or nursing, (5) persons deprived of their liberty or under guardianship, 6) impossibility to submit to the medical follow-up of the trial for geographical, social or psychological reasons. 7) patient who underwent cervical surgery for any cause 8) patient with cervical radiotherapy 9) patient unable to undergo cervical lymph node dissection 10) patient treated for another cancer outside the vads within a period of less than 6 months.
postoperative pain in laparoscopic radical prostatectomy surgery with tranexamic acid: analgesia? hiperalgesia?

Conditions: Pharmacological Action

Summary: prostate cancer is the most diagnosed cancer among men today. radical prostatectomy is a surgery that significantly reduces disease-related mortality. the laparoscopic technique, on the other hand, is preferred because it shortens the hospital stay, faster recovery and less postoperative pain.in this study, it was planned to investigate the analgesic or hyperalgesic effects of tranexamic acid, which is widely used in the management of bleeding in trauma, orthopedic, genitourinary and gynecological surgeries. routine noninvasive monitoring (ecg, spo2, nibp) will be performed when participatient are taken to the operating table without premedication. after midazolam is administered, intubation will be performed by administering 1mg/kg lidocaine, 3mg/kg propofol, 2mcg/kg fentanyl, 0.6mg/kg rocuronium. anesthesia will be maintained with desflurane with a mac of 1. a 0.1-0.5 mcg/kg/min remifentanil infusion will be administered by targeting 40-60 values with bis monitoring. after intubation, 15mg/kg tranexamic acid will be given 10 minutes before the incision, and 100 mg/h infusion will be administered until the skin is closed. the control group will be given 100 ml of saline.1mg/kg tramadol and 1gr parol will be administered 30 minutes before the end of the operation. the primary objectives of the study were to learn the vas (visual analog scale) score at 0.6,12, 24,48,72 hours, time to first analgesic requirement, and analgesic requirement within 24 hours. secondary purposes are to determine the amount of antiemetic used, at the beginning of the operation, hg at the first hour and postoperative 6 hours, complications and side effects (such as dvt, pulmonary embolism).

prostate cancer is the most diagnosed cancer among men today. radical prostatectomy is a surgery that significantly reduces disease-related mortality. the laparoscopic technique, on the other hand, is preferred because it shortens the hospital stay, faster recovery and less postoperative pain.in this study, it was planned to investigate the analgesic or hyperalgesic effects of tranexamic acid, which is widely used in the management of bleeding in trauma, orthopedic, genitourinary and gynecological surgeries

Eligibility criteria:
inclusion criteria: * elective laparoscopic radical prostatectomy will be performed; surgeon with more than 10 years of laparoscopic prostatectomy experience * participant bmi(weight/height2)(kg/m2)\<35 * asa2-3 * participant age\>18 * participant age\<75 exclusion criteria: * coagulation disorder, * chronic renal failure, * patients allergic to tranexamic acid, * participant age\<18 * participant age\>75, * participant bmi(weight/height2)(kg/m2)\>35, * surgeon with less than 10 years of laparoscopic prostatectomy experience, * patients who had a cerebral, coronary and thromboembolic event within 6 months before the operation
correlation of molecular biomarkers with biopsy findings and outcomes in renal transplant recipients

Conditions: Delayed Graft Function

Summary: this is a single-center, prospective, non-randomized, observational study to evaluate specific proteogenomic biomarker panels for acute rejection (ar) and chronic allograft nephropathy/interstitial fibrosis and tubular atrophy (can/ifta) in blood, urine and kidney tissue (biopsy) in kidney transplant recipients. proteogenomic profiles will be routinely monitored over one year after enrollment.

objective: the objective of this phase of the study is to allow the clinical site to gain familiarity with patient recruitment, sample and data collection, and interpretation of the proteogenomic biomarker report provided, through retrospective analysis. this phase of the study will provide a platform for the transplant physicians to gain confidence with the format, logistics, and potential use of the biomarker tests on blood and tissue.

Eligibility criteria:
inclusion criteria: patients who meet all of the following criteria are eligible for enrollment as study participants: 1. male and female recipients of all races, ≥18 years of age. 2. patients undergoing primary or subsequent deceased-donor or living donor kidney transplantation. 3. subject and/or guardian must be able to provide informed consent. 4. subject and/or guardian must be able to comply with the study protocol. exclusion criteria: 1. need for combined organ transplantation with an extra-renal organ and/or islet cell transplant. 2. recipients of previous non-renal solid organ and/or islet cell transplantation 3. infection with hiv. 4. inability or unwillingness of a participant and/or guardian to provide informed consent -

Keywords: renal biopsy elevated serum creatinine proteinuria
evaluation of deposits on contact lenses worn daily wear

Conditions: Refractive Error

Summary: the purpose of this study was to measure front surface deposits on contact lenses when worn for ten hours.


Eligibility criteria:
inclusion criteria: * 18 years or older. * visual acuity correctable to 20/30 (snellen) or better in each eye at distance with contact lenses. * successfully wearing hydrogel or silicone hydrogel contact lenses prior to enrollment in the study. * other protocol-defined inclusion criteria may apply. exclusion criteria: * evidence or history of keratitis (dendritic keratitis); viral disease of the cornea and/or conjunctiva; acute bacterial disease of the cornea and/or conjunctiva and/or eyelids; infection of the eye; and/or fungal disease of the eye. * one functional eye or a monofit lens. * ocular conditions such as active acute blepharitis, conjunctival infections, and iritis. * any slit-lamp finding score of (1) at the screening visit as defined in protocol. * use of concomitant topical ocular prescription or over-the-counter (otc) ocular medications. * history of seasonal allergies with significant ocular side effects which may have an adverse impact on contact lens wear. * other protocol-defined exclusion criteria may apply.

Keywords: contact lens deposits soft contact lenses myopia
ultrasound-guided thermal ablation for bethesda iii/iv thyroid nodules

Conditions: Thyroid Nodule

Summary: to evaluate the long-term outcomes of ultrasound-guided thermal ablation for bethesda iii/iv thyroid nodules

to evaluate and predict the long-term clinical outcomes of ultrasound-guided thermal ablation for bethesda iii/iv thyroid nodules

Eligibility criteria:
inclusion criteria: 1. confirmation of bethesda iii or iv on fine- needle aspiration and negative on braf v600e test 2. no clinical or imaging evidences of extrathyroidal extension, lymph node metastasis and distant metastasis on ultrasound, neck and chest ct 3. refusal or ineligibility for surgery 4. follow-up time ≥12 months exclusion criteria: 1. follicular neoplasm or malignancy findings on biopsy 2. no suspicious of malignancy in us 3. patients with contra-lateral vocal cord paralysis 4. follow- up time less than 12 months
assessment of trace elements, systemic inflammation and electrolytes

Conditions: Copd

Summary: copd is one of the most common causes of health problems worldwide. it is a disease that is associated with several systemic features that affect its morbidity and mortality.

the most prominent features of copd are systemic inflammation and oxidative stress. there is growing interest in establishing the significance of systemic inflammatory biomarkers in copd patients, as they could be useful in evaluating exacerbations, monitoring disease progression, and evaluating treatment outcomes. c-reactive protein (crp) is a biomarker for systemic inflammation, produced mostly by hepatocytes in response to tissue injury or inflammation. tumor necrosis factor - alpha (tnf-α) is a key modulator of the immune system's response to infection. at the sites of inflammation, this cytokine regulates the function of poly-morphs and lymphocytes, with essentially protective benefits for the host. increased tnf-α production may enhance an injury process locally and also elevated circulating levels may have negative systemic consequences. trace elements are hypothesized to play a role in the pathogenesis of many diseases, either directly or indirectly. trace elements play an important function in the inhibition and activation of enzyme processes . zinc, for example, is a co-factor for various enzymes and is important for cell membrane stability, protein synthesis, proper tissue growth, and nucleic acid metabolism. severity of copd exacerbation is associated with increased levels of copper (cu) and zinc (zn). patients with copd are liable for various electrolyte derangements, especially during exacerbations. hyponatremia is typically observed in the final stages of copd. hypokalemia may also occur independently or concomitantly with hyponatremia, and because magnesium plays a role in muscle tone, a drop in magnesium levels in copd is a component that reduces respiratory muscle function and causes muscle fatigue.

Eligibility criteria:
inclusion criteria: * copd patients exclusion criteria: * patients with cardiovascular diseases, * diabetes mellitus, * chronic kidney disease, * chronic liver disease, * collagen vascular diseases, * cancer, * currently smoking, * current pneumonia or inflammation, or refused to participate in the study

Keywords: copd biomarkers trace elements electrolytes
the safety and efficacy of coenzyme i for injection in promoting hematopoietic recovery of patients after sucbt

Conditions: Hematopoietic Recovery

Summary: to assess the safety and efficacy of coenzyme i for injection in promoting hematopoietic recovery after single-unit unrelated cord blood transplantation in hematological malignancies.

a single-center, open-label, dose-escalation study to assess the safety and efficacy of coenzyme i for injection in promoting hematopoietic recovery after single-unit unrelated cord blood transplantation in hematological malignancies.

Eligibility criteria:
inclusion criteria: * age between 18 and 60 years (inclusive) at screening; gender is not restricted; * diagnosed with hematological malignancies to receive sucbt for the first time; * no severe organ failure and no active infections * ecog performance status of 0-2; * voluntarily participating in the clinical trial, with full understanding of the trial details and having signed the informed consent form. exclusion criteria: * those with severe organ dysfunction or disease, such as severe disease and dysfunction of the heart, liver, kidneys and pancreas; * pregnant patients; * patients and/or authorised family members who refuse to receive coenzyme i for injection; * any life-threatening disease, physical condition, or organ system dysfunction that, in the opinion of the investigator, may compromise patient safety and put the results of the study at undue risk; drug-dependent individuals; patients with uncontrolled psychiatric disorders; and individuals with cognitive impairment; * participants in other clinical studies affecting hematopoietic recovery within 3 months; * those who are considered by the investigator to be unsuitable for enrolment (e.g., those who anticipate that the patient will not be able to adhere to the examination and treatment due to financial or other issues).

Keywords: hematopoietic recovery, sucbt